Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;191(2):559-562.
doi: 10.1007/s11845-021-02631-1. Epub 2021 May 12.

Delivery of systemic anti-cancer therapy during the COVID-19 pandemic

Orla Fitzpatrick  1   2 , Roisin Ní Dhonaill  3   4 , Anna Linehan  3   4 , Zac Coyne  3   4 , Maeve Hennessy  3   4 , Maeve Clarke  3   4 , Elizabeth McGee  3   4 , Fiona Barrett  3   4 , Deborah O'Doherty  3   4 , Carla Matassa  3   4 , Teresa Doyle  3   4 , Allyson Christie  3   4 , Bryan Hennessy  3   4 , Liam Grogan  3   4 , Patrick G Morris  3   4 , Oscar S Breathnach  3   4 , Darren Cowzer  3   4
Affiliations

Delivery of systemic anti-cancer therapy during the COVID-19 pandemic

Orla Fitzpatrick et al. Ir J Med Sci. 2022 Apr.

Abstract

Background: The first confirmed case of COVID-19 in Ireland was on February 29th 2020. From March until late April, the number of cases increased exponentially. The delivery of anti-cancer therapy during the COVID-19 pandemic was extremely challenging. In order to balance the benefits of continuing anti-cancer therapy with the associated increased hospital visits, combined with the risk of COVID-19 infection, we undertook a series of system changes in the delivery of cancer care.

Methods: Patients who attended our dayward over a 4-month period were included. Data were obtained from patient and chemotherapy prescribing records. Patients were screened for symptoms of COVID-19 at two separate timepoints: prior to their visit via telephone, and using a symptom questionnaire on arrival at the hospital. If patients displayed COVID-19 symptoms, they were isolated and a viral swab arranged.

Results: A total of 456 patients attended from January 1st to April 30th. The numbers of visits from January to April were 601, 586, 575, and 607, respectively. During this period, there were 2369 patient visits to the dayward and 1953 (82%) intravenous regimens administered. Of the 416 visits that did not lead to treatment, 114 (27%) were scheduled non-treatment review visits, 194 (47%) treatments were held due to disease-related illness, and 108 (26%) treatments were held due to treatment-related complications. Screening measurements were implemented on March 18th due to rising COVID-19 prevalence in the general population. Overall, 53 treatments were held due to the screening process: 19 patients (36%) elicited COVID-19 symptoms via telephone screening; 34 patients (64%) were symptomatic in our pre-assessment area and referred for swabs, of which 4 were positive. Those with a negative swab were rescheduled for chemotherapy the following week.

Conclusions: With careful systematic changes, safe and continued delivery of systemic anti-cancer therapy during the COVID-19 pandemic is possible.

Keywords: COVID-19; Oncology; Screening; Treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The total number of patient visits per month attending the day oncology ward for systemic anti-cancer therapy during the COVID-19 pandemic
See this image and copyright information in PMC

References

    1. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003–e1017. doi: 10.1016/S2214-109X(20)30264-3. - DOI - PMC - PubMed
    1. Wang H, Zhang L (2020) Risk of COVID-19 for patients with cancer. Vol. 21, The Lancet Oncol. p. e181. Available from: 10.1016/s1470-2045(20)30149-2 - PMC - PubMed
    1. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. - PMC - PubMed
    1. Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–559. doi: 10.1200/GO.20.00097. - DOI - PMC - PubMed
    1. Jee J, Foote MB, Lumish M et al (2020) Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol JCO2001307 - PMC - PubMed